303 related articles for article (PubMed ID: 28049532)
21. Radiosensitization of NSCLC cells to X-rays and carbon ions by the CHK1/CHK2 inhibitor AZD7762, Honokiol and Tunicamycin.
Liu B; Chen W; Li H; Li F; Jin X; Li Q
Radiat Environ Biophys; 2020 Nov; 59(4):723-732. PubMed ID: 32857208
[TBL] [Abstract][Full Text] [Related]
22. Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening.
Guzi TJ; Paruch K; Dwyer MP; Labroli M; Shanahan F; Davis N; Taricani L; Wiswell D; Seghezzi W; Penaflor E; Bhagwat B; Wang W; Gu D; Hsieh Y; Lee S; Liu M; Parry D
Mol Cancer Ther; 2011 Apr; 10(4):591-602. PubMed ID: 21321066
[TBL] [Abstract][Full Text] [Related]
23. Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors.
Sausville E; Lorusso P; Carducci M; Carter J; Quinn MF; Malburg L; Azad N; Cosgrove D; Knight R; Barker P; Zabludoff S; Agbo F; Oakes P; Senderowicz A
Cancer Chemother Pharmacol; 2014 Mar; 73(3):539-49. PubMed ID: 24448638
[TBL] [Abstract][Full Text] [Related]
24. Birinapant (TL32711) Improves Responses to GEM/AZD7762 Combination Therapy in Triple-negative Breast Cancer Cell Lines.
Min DJ; He S; Green JE
Anticancer Res; 2016 Jun; 36(6):2649-57. PubMed ID: 27272773
[TBL] [Abstract][Full Text] [Related]
25. Effects of a checkpoint kinase inhibitor, AZD7762, on tumor suppression and bone remodeling.
Wang L; Wang Y; Chen A; Jalali A; Liu S; Guo Y; Na S; Nakshatri H; Li BY; Yokota H
Int J Oncol; 2018 Sep; 53(3):1001-1012. PubMed ID: 30015873
[TBL] [Abstract][Full Text] [Related]
26. Combined use of subclinical hydroxyurea and CHK1 inhibitor effectively controls melanoma and lung cancer progression, with reduced normal tissue toxicity compared to gemcitabine.
Oo ZY; Proctor M; Stevenson AJ; Nazareth D; Fernando M; Daignault SM; Lanagan C; Walpole S; Bonazzi V; Škalamera D; Snell C; Haass NK; Larsen JE; Gabrielli B
Mol Oncol; 2019 Jul; 13(7):1503-1518. PubMed ID: 31044505
[TBL] [Abstract][Full Text] [Related]
27. Pristimerin synergizes with gemcitabine through abrogating Chk1/53BP1-mediated DNA repair in pancreatic cancer cells.
Jiang Z; Zhao Y; Zhao Y; Liu Y; Tao L
Food Chem Toxicol; 2021 Jan; 147():111919. PubMed ID: 33301843
[TBL] [Abstract][Full Text] [Related]
28. MLN4924 Synergistically Enhances Cisplatin-induced Cytotoxicity via JNK and Bcl-xL Pathways in Human Urothelial Carcinoma.
Ho IL; Kuo KL; Liu SH; Chang HC; Hsieh JT; Wu JT; Chiang CK; Lin WC; Tsai YC; Chou CT; Hsu CH; Pu YS; Shi CS; Huang KH
Sci Rep; 2015 Nov; 5():16948. PubMed ID: 26592553
[TBL] [Abstract][Full Text] [Related]
29. Phase I, dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumours.
Seto T; Esaki T; Hirai F; Arita S; Nosaki K; Makiyama A; Kometani T; Fujimoto C; Hamatake M; Takeoka H; Agbo F; Shi X
Cancer Chemother Pharmacol; 2013 Sep; 72(3):619-27. PubMed ID: 23892959
[TBL] [Abstract][Full Text] [Related]
30. The Chk1 inhibitor AZD7762 sensitises p53 mutant breast cancer cells to radiation in vitro and in vivo.
Ma Z; Yao G; Zhou B; Fan Y; Gao S; Feng X
Mol Med Rep; 2012 Oct; 6(4):897-903. PubMed ID: 22825736
[TBL] [Abstract][Full Text] [Related]
31. Suppression of the FA pathway combined with CHK1 inhibitor hypersensitize lung cancer cells to gemcitabine.
Dai CH; Wang Y; Chen P; Jiang Q; Lan T; Li MY; Su JY; Wu Y; Li J
Sci Rep; 2017 Nov; 7(1):15031. PubMed ID: 29118324
[TBL] [Abstract][Full Text] [Related]
32. UBE2M-mediated p27(Kip1) degradation in gemcitabine cytotoxicity.
Huang AM; Kao YT; Toh S; Lin PY; Chou CH; Hu HT; Lu CY; Liou JY; Chao SY; Hour TC; Pu YS
Biochem Pharmacol; 2011 Jul; 82(1):35-42. PubMed ID: 21477582
[TBL] [Abstract][Full Text] [Related]
33. The marine triterpene glycoside frondoside A induces p53-independent apoptosis and inhibits autophagy in urothelial carcinoma cells.
Dyshlovoy SA; Madanchi R; Hauschild J; Otte K; Alsdorf WH; Schumacher U; Kalinin VI; Silchenko AS; Avilov SA; Honecker F; Stonik VA; Bokemeyer C; von Amsberg G
BMC Cancer; 2017 Feb; 17(1):93. PubMed ID: 28143426
[TBL] [Abstract][Full Text] [Related]
34. The growth inhibition of hepatocellular and cholangiocellular carcinoma cells by gemcitabine and the roles of extracellular signal-regulated and checkpoint kinases.
Matsumoto K; Nagahara T; Okano J; Murawaki Y
Oncol Rep; 2008 Oct; 20(4):863-72. PubMed ID: 18813828
[TBL] [Abstract][Full Text] [Related]
35. In vitro and in vivo radiation sensitization of human tumor cells by a novel checkpoint kinase inhibitor, AZD7762.
Mitchell JB; Choudhuri R; Fabre K; Sowers AL; Citrin D; Zabludoff SD; Cook JA
Clin Cancer Res; 2010 Apr; 16(7):2076-84. PubMed ID: 20233881
[TBL] [Abstract][Full Text] [Related]
36. A novel mechanism of checkpoint abrogation conferred by Chk1 downregulation.
Xiao Z; Xue J; Sowin TJ; Rosenberg SH; Zhang H
Oncogene; 2005 Feb; 24(8):1403-11. PubMed ID: 15608676
[TBL] [Abstract][Full Text] [Related]
37. Poly(ADP-ribose) polymerase 1 modulates the lethality of CHK1 inhibitors in carcinoma cells.
Mitchell C; Park M; Eulitt P; Yang C; Yacoub A; Dent P
Mol Pharmacol; 2010 Nov; 78(5):909-17. PubMed ID: 20696794
[TBL] [Abstract][Full Text] [Related]
38. Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models.
Ma CX; Cai S; Li S; Ryan CE; Guo Z; Schaiff WT; Lin L; Hoog J; Goiffon RJ; Prat A; Aft RL; Ellis MJ; Piwnica-Worms H
J Clin Invest; 2012 Apr; 122(4):1541-52. PubMed ID: 22446188
[TBL] [Abstract][Full Text] [Related]
39. Preclinical development of the novel Chk1 inhibitor SCH900776 in combination with DNA-damaging agents and antimetabolites.
Montano R; Chung I; Garner KM; Parry D; Eastman A
Mol Cancer Ther; 2012 Feb; 11(2):427-38. PubMed ID: 22203733
[TBL] [Abstract][Full Text] [Related]
40. The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma.
Walton MI; Eve PD; Hayes A; Henley AT; Valenti MR; De Haven Brandon AK; Box G; Boxall KJ; Tall M; Swales K; Matthews TP; McHardy T; Lainchbury M; Osborne J; Hunter JE; Perkins ND; Aherne GW; Reader JC; Raynaud FI; Eccles SA; Collins I; Garrett MD
Oncotarget; 2016 Jan; 7(3):2329-42. PubMed ID: 26295308
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]